Browse by author
Lookup NU author(s): Dr Simon Pridgeon, Professor Rakesh Heer, Gordon Taylor, Professor Herbie Newell, Kieran O'Toole, Professor Alan Boddy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BACKGROUND: Thiothymidine (S(4)TdR) can be incorporated into DNA and sensitise cells to DNA damage and cell death following exposure to UVA light. Studies were performed to determine if the combination of S(4)TdR and UVA could be an effective treatment for bladder cancer. METHODS: Uptake and incorporation of S(4)TdR was determined in rat and human bladder tumour cell lines. Measures of DNA crosslinking and apoptosis were also performed. In vivo activity of the combination of S(4)TdR and UVA was investigated in an orthotopic model of bladder cancer in rats. RESULTS: Thiothymidine (200 mM) replaced up to 0.63% of thymidine in rat and tumour bladder cancer cells. The combination of S4TdR (10-200 mu M) and UVA (1-5 kJm(-2)) caused apoptosis and cell death at doses that were not toxic alone. Addition of raltitrexed (Astra Zeneca, Alderley Edge, Cheshire, UK) increased the incorporation of S(4)TdR into DNA (up to 20-fold at IC5) and further sensitised cells to UVA. Cytotoxic effect was associated with crosslinking of DNA, at least partially to protein. Intravenous administration of S(4)TdR, in combination with UVA delivered directly to the bladder, resulted in an antitumour effect in three of five animals treated. CONCLUSION: These data indicate that the combination of S(4)TdR and UVA has potential as a treatment for bladder cancer, and give some insight into the mechanism of action. Further work is necessary to optimise the delivery of the two components. British Journal of Cancer (2011) 104, 1869-1876. doi:10.1038/bjc.2011.180 www.bjcancer.com Published online 24 May 2011 (C) 2011 Cancer Research UK
Author(s): Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2011
Volume: 104
Issue: 12
Pages: 1869-1876
Print publication date: 24/05/2011
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/bjc.2011.180
DOI: 10.1038/bjc.2011.180
Altmetrics provided by Altmetric